Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2024 18:40 ET | Source: Vaxcyte, Inc.

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
August 06, 2024 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

-- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or...
July 02, 2024 08:30 ET | Source: Vaxcyte, Inc.

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte appoints John Furey to Board of Directors.
May 08, 2024 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout,...
April 02, 2024 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
March 04, 2024 08:30 ET | Source: Vaxcyte, Inc.

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose...
February 27, 2024 16:01 ET | Source: Vaxcyte, Inc.

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult...
February 15, 2024 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
February 02, 2024 18:39 ET | Source: Vaxcyte, Inc.

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
February 01, 2024 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...